Circulating lipopolysaccharide-binding protein (LBP), a metabolic endotoxemia marker, was identified as an independent predictor of atherosclerosis. Although increases in carotid intima-media 
Introduction
Obstructive sleep apnea (OSA) is characterized by repeated episodes of upper airway occlusion during sleep, which are associated with hypoxia and arousals from sleep. Acutely, repetitive apneas and hypopneas trigger surges in sympathetic nervous system activity, blood pressure and heart rate. Chronically, patients with OSA are at increased risk for arterial hypertension, stroke, and myocardial ischemia and have an increased cardiovascular morbidity and mortality (Shah et al. 2010 , Punjabi et al. 2009 , Marin et al. 2005 . In addition, signs of subclinical atherosclerosis as evidenced by increased carotid intima-media thickness (CIMT) were reported in OSA including patients with no overt cardiovascular disease (Monneret et al. 2010 , Fox et al. 2014 , Damiani et al. 2015 , Drager et al. 2005 .
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Metabolic endotoxemia reflected by serum lipopolysaccharide-binding protein (LBP) levels was identified to represent an independent predictor of coronary atherosclerosis in the LURIC study (Lepper et al. 2014) thus extending the list of recognized pathogenetic mechanisms of atherosclerosis such as aging, obesity-related metabolic disturbances and inflammatory processes (Libby 2002) . Originally, Cani et al. (2008) identified bacterial lipopolysaccharide (LPS) as a triggering factor of insulin resistance and weight gain, and defined its negative effects as "metabolic endotoxemia". LBP binds LPS, and elevated circulating concentrations of this biomarker are considered a marker of metabolic endotoxemia in clinical studies (GonzalezQuintela et al. 2013) . Several reports documented an association between serum LBP and prevalent coronary artery disease, and identified LBP as an independent predictor of coronary atherosclerosis (Lepper et al. 2011 , Lepper et al. 2007 , Szeto et al. 2008 , Serrano et al. 2013 . Nevertheless, the effects of OSA on serum LBP and the potential links between metabolic endotoxemia and CIMT in such patients remain largely unexplored. Therefore, we investigated the effects of OSA severity on serum LBP, and tested the hypothesis that serum LBP concentrations relate to CIMT in patients with OSA.
Methods

Subjects
The study was conducted in the sleep unit at the tertiary referral university hospital. Clinically stable men who had been referred for evaluation of suspected OSA were enrolled to the study. Exclusion criteria were history of known cardiovascular disease (CVD), angina, myocardial infarction, stroke, congestive heart failure, chronic respiratory diseases other than OSA, type 1 or 2 diabetes, hereditary metabolic disorders, hypothyroidism, chronic inflammatory diseases and regular use of sedatives, antidepressant or antipsychotic medication or alcohol. The history was retrieved from complete patients' charts as provided by general practitioners. Anthropometric measurements were obtained in the morning after the polysomnographic examination with the patient standing erect. Body weight, height, neck circumference, waist circumference and hip circumference were measured and recorded. Neck circumference was measured at the level of the cricothyroid membrane; waist circumference at the midpoint between the costal margin and the iliac crest at the end of normal expiration; hip circumference at the level of the greater trochanter. Body mass index (BMI) was defined as weight/height 2 (kg/m 2 ). The waist-to-hip ratio (WHR) was also calculated. The study was in agreement with Helsinki protocol and was approved by the L. Pasteur University Hospital ethics committee. All subjects provided written informed consent before entry to the study.
Polysomnography
All participants underwent attended diagnostic overnight polysomnography (Alice 4; Respironics Inc., Murrysville, Pennsylvania, USA), comprising continuous recording of electroencephalograph, electrooculography, electromyography, electrocardiography, thoracic and abdominal impedance belts for respiratory movements, thermistor for nasal and oral airflow, pulse oximetry and microphone for snoring. All records were scored manually following the American Academy for Sleep Medicine (AASM) 2012 guidelines (Berry et al. 2012) . Apnea was identified as a drop in airflow of ≥90 % from the baseline excursion for ≥10 s; hypopnea was defined as a reduction in airflow of ≥50 % of baseline for ≥10 s accompanied either by a decrease in hemoglobin saturation for ≥3 %, an EEG-recorded arousal, or both. The apnoe-hypopnoe index (AHI) was defined as the number of apnoe and hypopnoe events per hour of sleep. Oxygen desaturation index (ODI) was defined as the number of oxygen desaturations of hemoglobin of ≥3 % per hour of sleep. In addition, the length of time with an arterial oxygen saturation measured by pulse oximetry (SpO 2 ) <90 % was used to assess the degree of nocturnal hypoxia. The classification of OSA severity was based on AASM guidelines: Mild: AHI≥5 and <15 episodes.h -1 ; moderate: AHI≥15 and <30 episodes.h -1 , and severe:
AHI≥30 episodes.h -1 (Berry et al. 2012) .
Biochemical measurements
Peripheral venous blood samples were collected between 6-7 a.m. following an overnight 12 h fast and polysomnography. Blood sample was taken from the antecubital vein and after immediate centrifugation, aliquots of plasma and serum were stored at -70 °C until analysis. Fasting cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, apolipoprotein A-I (ApoA-I), and apolipoprotein B (ApoB) were measured by routine enzymatic methods. Low-density lipoprotein (LDL) cholesterol was derived using the Friedewald equation. Serum insulin was determined with electrochemiluminiscence immunoassay kits (Elecsys) on Roche Elecsys 1010/2010 and modular analytics E170 immunoassay analyzers (Roche Diagnostics GmbH, Mannheim, Germany); plasma glucose was measured by the glucose oxidase method on a Beckman autoanalyzer. Insulin resistance was estimated by the homeostasis model assessment (HOMA-IR) using the following formula: fasting serum insulin (mU.l -1 ) x fasting plasma glucose (mmol.l -1 )/22.5 (Gayoso-Diz et al. 2013) . LBP levels were assessed using a commercially available kit based on murine monoclonal antibodies specific for human LBP (Human LBP ELISA, Abnova, Taipei City, Taiwan).
Carotid intima-media thickness
Measurement of CIMT was done by high-resolution B-mode ultrasound system (Philips HD11XE) equipped with a linear array 7 MHz transducer. 3-lead electrocardiographic signal was obtained along with ultrasound scanning and CIMT was measured at the end-diastole. Semiautomatic border detection program QLab © was used for offline CIMT measurement on the segment of the common carotid artery (CCA) free of atherosclerotic plaque with clearly defined lumen-intima and media-adventitia interfaces. The measurement was done on the far wall of CCA at a distance of at least 10 mm below its distal end. Values from right and left CIMT were calculated as the mean of three measurements. Average CIMT (mm) was calculated as the mean of the right and left CIMT values (Touboul et al. 2012) .
Statistical analysis
Analyses were conducted using SPSS software for Windows (version 14.0; IBM, Chicago, Illinois, USA); two-tailed p<0.05 was considered significant. The data of continuous variables are presented as mean ± SD; differences between the groups were analyzed using analysis of variance (ANOVA). Kolmogorov-Smirnov test was used to check for normality of the values distribution within each variable. Chi-square test was used to compare the proportion of categorical variables between groups. Correlation analyses were performed using the Pearson product moment correlation method. Multiple linear regression models were used with LBP as a dependent variable and age, WHR, smoking, hypertension, ODI, serum fasting glucose, triglycerides and HDL cholesterol levels as independent variables. Furthermore, multiple linear regression models were used to assess independent predictors of CIMT.
Results
Characteristics of the subjects
One hundred and seventeen subjects participated in the study; 10 had no OSA, 50 suffered from mild to moderate, and 57 from severe OSA. Basic demographic characteristics and polysomnographic findings in the study groups are summarized in Table 1 . Higher age, BMI, neck circumference, waist-to-hip ratio, systolic and diastolic blood pressure (BP) were all associated with greater severity of OSA. In the entire cohort, 35 % of patients were hypertensive, and were using the following anti-hypertensive drugs: angiotensin-converting enzyme inhibitors (n=25), sartans (n=6), diuretics (n=6), calcium-antagonists (n=14) and beta-blockers (n=17).
Serum lipids and insulin sensitivity
Serum LDL/HDL ratio, atherogenic index, ApoB levels, and ApoB/ApoA ratio significantly increased from patients without OSA to those with mildmoderate and severe OSA (p=0.019, p=0.005, p=0.030, p=0.046, respectively) ( Table 2 ). In addition, fasting glucose, insulin and HOMA-IR all increased with greater severity of OSA; patients with severe OSA had significantly higher HOMA-IR compared to participants with no OSA (p<0.05).
Circulating LBP
Circulating LBP concentrations increased from patients without OSA to those with mild-moderate and severe OSA (from 32.1±10.3 to 32.3±10.9 to 38.1±10.3 μg.ml -1 , p=0.015) (Fig. 1) . Patients with severe OSA had significantly higher serum LBP compared to patients with mild-moderate OSA (p<0.05). After adjustments for age and BMI, serum LBP levels were significantly related to indices of central obesity (neck circumference and WHR), and to ODI (Table 3) . ODI (p=0.023) and WHR (p=0.039) predicted serum LBP levels independently of age, smoking, hypertension, serum fasting glucose, triglycerides and HDL cholesterol levels in the multivariate regression analysis (p of the model=0.002, r 2 =0.154). We also analyzed an independent effect of an interaction term (WHR*ODI) on serum LBP levels, nevertheless, this interaction term did not reach statistical significance in the multivariate analysis.
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Values are given as the mean ± SD, if not indicated otherwise. * p<0.05 compared to no OSA. † p<0.05 compared to mild -moderate OSA. OSA, obstructive sleep apnea; BMI, body mass index; BP, blood pressure; NREM, non-rapid eye movement; S1, stage 1; S2, stage 2; SWS, slow wave sleep; REM, rapid eye movement; AHI, apnea/hypopnea index; ODI, oxygen desaturation index; SpO2, arterial oxygen saturation measured by pulse oximetry. 
Carotid intima-media thickness
Both the right and left common CIMT increased from participants with no OSA to patients with mildmoderate and severe OSA (p=0.006; p=0.002, respectively) ( Values are given as the mean ± SD. * p<0.05 compared to no OSA. † p<0.05 compared to mild -moderate OSA. OSA, obstructive sleep apnea; CIMT, carotid intima-media thickness. 
Discussion
The present study provides a novel observation on the relationship between OSA severity, endotoxemia and subclinical atherosclerosis in patients with OSA. Our data demonstrate increases in serum LBP concentrations in patients with severe OSA, in association with increases in CIMT. OSA severity as reflected by ODI was related to metabolic endotoxemia independently of obesity. Furthermore, serum LBP levels predicted CIMT independently of other known risk factors of atherosclerosis including obesity. Recently, low-grade endotoxemia was observed in children with OSA (Kheirandish-Gozal et al. 2014) , and relationships between snoring (but no OSA) and higher LBP were demonstrated in adults (Sun et al. 2011) . Nevertheless, these studies did not evaluate an independent effect of OSA on LBP levels, and in addition no direct assessment of clinical or subclinical atherosclerosis was performed. Therefore, by concomitant assessment of OSA severity, serum LBP levels and CIMT, our findings are the first to suggest that OSA severity as reflected by ODI relates to metabolic endotoxemia, and that endotoxemia is linked to increases in CIMT in adult patients with OSA. Importantly, the observed relationships were independent of the confounding effects of obesity.
LBP is an endogenously produced biomarker produced by hepatocytes, intestinal epithelial cells and adipocytes in response to intestinal microbial translocation, i.e. in response to the movement of gut microbial species or their products across intestinal mucosal barrier without overt bacteremia (Cani et al. 2008 , Teixeira et al. 2012 , Patel et al. 2015 . LBP binds LPS in various pathologic states including obesity and insulin resistance, which are recognized as leading clinical conditions associated with endotoxemia (Kim et al. 2016 , Boutagy et al. 2016 . In agreement with previous reports our data demonstrate relationships between serum LBP and parameters of central obesity and insulin sensitivity (Gonzalez-Quintela et al. 2013 , Kheirandish-Gozal et al. 2014 , Sun et al. 2011 , Zhu et al. 2016 , and extend these findings further by suggesting an independent effect of OSA on serum LBP levels. The presence of intermittent episodes of hypoxia during sleep due to the repetitive apnea-hypopneas is a hallmark of OSA that links this disorder to its comorbidities (Dewan et al. 2015) . Indeed, in our recent study we have documented that ODI provides a solid reflection of the degree of intermittent hypoxemia during sleep that predicts arterial hypertension in OSA patients (Tkacova et al. 2014) . The role of hypoxia is further supported by the present results that suggest that ODI is related to serum LBP levels independently of the confounding effects of central obesity and other confounders. Which mechanisms might link chronic hypoxia to increases in endotoxemia markers? Several pathogenetic pathways are likely involved such as hypoxia-induced deterioration in the intestinal barrier function (Chun et al. 2016 , Shah et al. 2016 , and activation of different cellular adaptive mechanisms in hepatocytes (Liu et al. 2014 . Hypoxia-inducible factor (HIF) transcription factors represent master regulators of the cellular responses to the hypoxia that might be key elements also in the control of immune cell metabolism and functionality (Palazon et al. 2014) . Nevertheless, assessment of these mechanisms was beyond the scope of the present investigation, and thus further studies are needed to explore the pathogenetic links between hypoxia and metabolic endotoxemia.
Recent studies identified serum LBP as a significant and independent predictor of cardiovascular morbidity and mortality which significantly increased the research and clinical interests in assessing circulating LBP levels. Serrano et al. (2013) documented a consistent association between serum LBP and the CIMT within the FLORINASH project. Moreover, Lepper et al. (2007) observed significantly increased LBP in patients with angiographically documented coronary disease compared with angiographically negative patients, and in another study demonstrated that circulating LBP was a significant and independent predictor of total and cardiovascular mortality (Lepper et al. 2011) . Moreover, consistent associations were observed between serum LBP and CIMT in other disorders such as patients in chronic peritoneal dialysis (Szeto et al. 2008 ). Our present report extends these previous observations by demonstrating increases in serum LBP in association with increased CIMT in patients with severe OSA, independently of other risk factors of atherosclerosis. To the best of our knowledge, this is the first study that reports a relationship between endotoxemia and subclinical atherosclerosis in patients with sleep disordered breathing, a condition associated with increased atherosclerotic morbidity and mortality (Marin et al. 2005 , Ayas et al. 2016 .
Multiple studies had linked OSA to the both traditional and novel risk factors of atherosclerosis such as arterial hypertension (Tkacova et al. 2014) , the Vol. 67 metabolic syndrome (Quian et al. 2016) , systemic inflammation and oxidative stress (DeMartino et al. 2016) . Our present findings coupled with reports of others (Lepper et al. 2011 , Serrano et al. 2013 raise the possibility that LBP might, indeed, represent an additional risk factor of atherosclerosis. A question arises about the pathogenetic role of LBP in the development of the atherosclerotic plaque. LBP is the first protein to encounter LPS and to deliver it to its cellular targets, and thus it seems to be the first step in activating proinflammatory cascade of innate immune responses, which plays an important role in the pathophysiology of atherosclerosis (Ding et al. 2014 . Nevertheless, further studies are needed to thoroughly investigate the role of LBP as a cardiovascular risk factor.
Studying a well-defined cohort of adult men with OSA who all underwent full attended overnight polysomnography represents one of the main strengths of this study. Importantly, for the assessment of CIMT we have used an automatically based method that is both precise and highly reproducible (Bauer et al. 2012) . There are several limitations to this study that need to be acknowledged. First, only a limited number of subjects were studied. However, compared to participants with no OSA, patients with severe OSA had mean CIMT values increased by 19 %, which was associated with increases in serum LBP by 12 %. Therefore, although our results are robust to gain some understanding on the role of LBP in OSA-related increases in CIMT, they should be considered preliminary and hypothesis generating. In addition, cross-sectional nature of the present study does not allow for the determination of time-course relationship between LBP and CIMT.
In conclusion, our study highlights associations between OSA severity, endotoxemia and CIMT in patients with OSA that are independent of other known risk factors of atherosclerosis including obesity. Further studies are needed to address the pathological mechanisms underlying the observed relationships in more details.
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